Title: NHS and Psilocybin: The Controversy Over Psychedelic Depression Treatments

Larissa Hope asserts that psilocybin, the psychoactive compound found in magic mushrooms, was instrumental in overcoming her severe mental health struggles. At age 17, Hope began her acting career on the television drama Skins, but the sudden attention triggered long-suppressed trauma. While standard antidepressants failed to provide relief, a clinically supervised dose of psilocybin proved to be a pivotal moment. Recalling the experience, Hope states, “When I experienced it, I burst out crying... It was the first time in my life I had ever felt a sense of belonging and safety in my body. I kept saying, ‘I'm home, I'm home’.” Nearly two decades later, she credits this experience, combined with therapy, for helping her manage suicidal ideation.

However, not all accounts are positive. Jules Evans, a university researcher, recounts a profoundly negative reaction to LSD during his youth. Although taken recreationally at age 18, the experience induced a “deluded” state characterized by paranoia. “I believed that everyone was talking about me, criticising me, judging me. I thought, I've permanently damaged myself; I've permanently lost my mind,” Evans recalls. He describes it as the most terrifying event of his life. Evans now leads the Challenging Psychedelic Experiences Project, supporting individuals who suffer adverse effects from psychedelics. He notes that he continued to struggle with social anxiety and panic attacks for years, eventually receiving a diagnosis of post-traumatic stress disorder (PTSD).

These contrasting narratives highlight the central dilemma confronting medical professionals, policymakers, and regulators: Should physicians be permitted to prescribe psychedelic substances, including magic mushrooms, for therapeutic purposes?

This question has gained urgency due to recent research suggesting that psychedelic drugs may offer benefits for conditions ranging from depression and obsessive-compulsive disorder to PTSD and addictions involving alcohol or gambling. Currently, the use of psychedelic medicine is prohibited except within authorized clinical trials or research settings. Since 2022, over 20 trials have evaluated various psychedelic treatments for these conditions. While many studies indicate positive outcomes, several have yielded mixed or inconclusive data, with only a handful showing no significant benefit on primary measures.

The UK medicines regulator is currently reviewing data from Compass Pathways, a UK biotech firm, regarding one of the largest psilocybin clinical trials. The results, expected later this year, will influence decisions on whether to ease current restrictions and permit the use of psychedelic medicines outside of research frameworks.

Prof Oliver Howes, chair of the Royal College of Psychiatrists' Psychopharmacology Committee, expresses optimism about the potential of these treatments within the NHS. “One of the key messages is that this is something we desperately need - more treatments and better treatments for mental health disorders,” he says. He notes that while small-scale studies have shown promise, the real advantage lies in the potential for faster action. “These treatments are really interesting because they've shown promise in these small-scale studies… and have the potential to work quicker.”

Despite this enthusiasm, experts urge restraint. A September 2025 report by the Royal College of Psychiatrists highlighted the potential risks associated with psychedelics. Medical professionals emphasize that beyond the legal prohibitions, self-administration of these drugs can be dangerous and harmful.

Source: BBC News Generated at: 2026-01-02 15:47:15 UTC